Document Type


Publication Date



Pharmacy and Pharmaceutical Sciences


Alzheimer’s disease (AD) is the most common cause of dementia, accounting for approximately 60~70% of dementia cases. AD afflicts more than 35.6 million individuals worldwide and is expected to increase to 65.7 million by 2030 and 115.4 million by 2050 1; AD is a serious public health problem that is causing increased health care costs worldwide. Typically, AD is a relentlessly progressive disorder that initially manifests as severe loss of memory, particularly episodic memory.2 The disorder is not curable at present, and the mechanisms driving development of AD are not fully understood. Therefore, there is an urgent need to develop and characterize relevant AD transgenic animal models to facilitate translational research and preclinical testing of therapeutic agents.3 Furthermore, it is imperative to discover the underlying mechanisms that exacerbate AD, which hinder mitigation efforts to reduce the health burden of this disease.


© 2018 Yoon Hee Cho